MRC1 and neoplasm: The subclass prototype for PDAC with immunogenicity and responsiveness to ICIs is MMR-d, which exhibits elevated levels of tumor mutation burden (TMB) and tumor infiltrating CD8 T-lymphocytes compared to MMR-intact PDAC (19, 20, 36).